- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03356834
Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF (SWITAF)
December 19, 2022 updated by: George Lau, Humanity and Health Research Centre
Change of Renal Function and Bone Mineral Density Marker in Chronic Hepatitis B Patients Switching From TDF to TAF vs. Maintaining TDF
In Chronic hepatitis B (CHB) patients receiving long-term sequential Neucleos(t)ides(NAs), majority of these CHB patients experienced drug resistance and switched to Tenofovir disoproxil fumaratate(TDF).
However, some of patients on long term TDF experienced impairment of renal function and bone mineral density.
After Tenofovir alafenamide(TAF) was in clinical practice, these group of patients got an clinical option to switch from TDF to TAF.
The investigators designed a prospective cohort study to evaluate the real life effectiveness and safety in participants with chronic HBV infection switch from TDF to TAF vs. maintaining on TDF.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Tenofovir disoproxil fumarate(TDF) have been associated with renal toxicity and reduced bone mineral density.
Tenofovir alafenamide(TAF) is a novel tenofovir prodrug that reduces tenofovir plasma concentrations by 90%, thereby decreasing off-target side-effects.
The investigators aimed to assess whether efficacy, safety, and tolerability were non-inferior in participants switched to TAF versus in those remaining on TDF.
This is a prospective clinical study.
Study Type
Interventional
Enrollment (Anticipated)
1000
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cheng Wang, M.D. PhD
- Phone Number: 21539831
- Email: wangcheng@hnhmgl.com
Study Contact Backup
- Name: Yudong Wang, PhD
- Phone Number: 21539831
- Email: dannywang@hnhmgl.com
Study Locations
-
-
-
Hong Kong, Hong Kong, 00852
- Recruiting
- Humanity and Health GI and Liver Centre
-
Contact:
- George KK Lau, MD
- Phone Number: (852)28613777
- Email: gkklau@netvigator.com
-
Principal Investigator:
- George KK Lau, MD
-
Contact:
- Cheng Wang, M.D, PhD
- Phone Number: 21539831
- Email: wangcheng@hnhmgl.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Chronic hepatitis B,
- Antiviral experienced,
- Currently on long term TDF anti-HBV treatment,
- HBV DNA < 6 log IU/ml (LLOD)
- Able to sign the consent form of anticipating in the study
Exclusion Criteria:
- Co-infected with HCV, HIV or other viral hepatitis,
- Diagnosis of HCC
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Maintaining on TDF
Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
|
300 mg tablet administered orally once daily
Other Names:
|
Experimental: TDF switch to TAF
Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Tenofovir Alafenamide(TAF) 25mg daily
|
25 mg tablet administered orally once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antiviral response of TAF
Time Frame: 60 months
|
Anti-HBV effectiveness of TAF compared with TDF in treatment experienced CHB patients
|
60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of renal function and bone mineral density in CHB patients switching to TAF
Time Frame: 60 months
|
Change of renal function and bone mineral density from baseline in CHB patients of TAF a group compared with TDF group
|
60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2017
Primary Completion (Anticipated)
October 1, 2023
Study Completion (Anticipated)
October 1, 2024
Study Registration Dates
First Submitted
September 20, 2017
First Submitted That Met QC Criteria
November 24, 2017
First Posted (Actual)
November 29, 2017
Study Record Updates
Last Update Posted (Actual)
December 21, 2022
Last Update Submitted That Met QC Criteria
December 19, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
Other Study ID Numbers
- HumanityHGLC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
Clinical Trials on Tenofovir alafenamide(TAF)
-
University of Maryland, BaltimoreGilead SciencesCompleted
-
Brigham and Women's HospitalBoston Medical Center; Tufts Medical CenterCompleted
-
Merck Sharp & Dohme LLCActive, not recruitingHIV-1 InfectionUnited States, Argentina, Canada, Chile, Colombia, France, Germany, Israel, Italy, Japan, South Africa, Spain, Taiwan
-
Merck Sharp & Dohme LLCCompletedHIV Preexposure ProphylaxisUnited States, Brazil, France, Japan, South Africa, Thailand, Peru
-
Hospital Italiano de Buenos AiresSociedad Argentina de Infectología (SADI) (Argentine Society of Infectious...UnknownCOVID-19 | Healthcare Workers | SARS-CoV 2Argentina
-
Midland Research Group, Inc.Gilead SciencesCompletedHuman Immunodeficiency VirusUnited States
-
Thomas Jefferson UniversityGilead SciencesActive, not recruiting
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Janssen Sciences Ireland UCCompleted
-
Gilead SciencesCompletedHIV-1 InfectionSpain, United States, France, Italy, Germany, Canada, United Kingdom, Belgium, Puerto Rico, Australia